Background: Coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been associated with cardiovascular features, which may be deteriorated in cancer patients. However, cardiac outcomes of cancer patients with COVID-19 have not been closely examined. Methods: We retrospectively assessed 1244 patients with COVID-19 from February 1st to August 31st (140 cancer and 1104 non-cancer patients). Demographic and clinical data were obtained and compared between cancer and non-cancer groups. Including the cardiac biomarkers, we also analyzed laboratory findings between these two groups. Risk factors for in hospital mortality were identified by multivariable COX regression models. Results: For cancer group, 56% were in severe and critical status with more diabetes and immune deficiency, while the proportion was 10% for non-cancer group. Cancer patients had increased levels of leukocyte, neutrophil count and BUN (all p<0.01), while lymphocyte count was significantly lower (p<0.001). The most common solid tumor types were gastrointestinal cancer (26%), lung cancer (21%), breast and reproductive cancer (both 19%). There is a rising for cardiac biomarkers, including Pro-BNP, cTnI, MYO, CK-MB, as well as D-Dimer in COVID-19 cancer population, especially in deceased cancer subjects. The 30-day in hospital mortality in cancer group was dramatically raised than that in non-cancer group (12.9% vs. 4.0%, p<0.01). In multivariable COX regression models, fever, disease severity status, underlying diseases were risk factors for mortality. Conclusion: COVID-19 patients with cancer relate to deteriorating conditions and poor cardiac outcomes accompanied by a high in-hospital mortality, which warrants more aggressive treatment.
Clinical Characteristics, Risk Factors and Cardiac Manifestations of Cancer Patients with COVID-19
